businessbriefs
SubjectsAll subjects on briefs.cloud →
Saved
Companies

Serum Institute of India

1966

The world’s largest vaccine maker by volume is not a tech disruptor — it’s a high-volume, low-margin public health utility run as a private company.

Worth your time?4/5Yes.Study the whole thing.What works, what does not, who it is for ↓
9:48in productionCh. 1 · Private since day one/ 9:48 · ceiling 15 min
4 chapters · 9:48Ceiling 15:00

The brief is written and checked. The video joins this page when it is cut.4 chapters · 1 min read · 9:48 planned

Read the brief

Serum Institute of India is the world's largest vaccine manufacturer by volume — a fact rooted in production capacity and multilateral procurement, not IP, pricing power, or domestic dominance. Its business model depends on high-volume, low-margin contracts with global health institutions. Nothing in the source material confirms profitability, cost structure, or innovation claims. It is infrastructure masquerading as enterprise.

CompaniesVaccinesSupply chainsBiographyVaccines across the network →
Chapters & takeaways4
  1. 1:17
    Private since day one

    It is a privately owned Indian biotech firm founded in 1966 — not a startup, not a state enterprise, and not a recent entrant.

  2. 2:45
    Volume, not velocity

    Scale comes from manufacturing volume across legacy and expanded vaccine lines — not novel platforms or proprietary delivery tech.

  3. 4:59
    Beyond vaccines

    Its non-vaccine products — antisera, blood plasma, hormones — are part of its output but receive no detail on scale, regulation, or market.

  4. 6:14
    Procured, not prescribed

    Its global role is defined by procurement, not policy: WHO, UNICEF, and PAHO used its vaccines as of 2014 — a statement of supply, not influence.

1 more chapterFewer chapters
Worth your time?

Yes. Study the whole thing.

4/ 5
What works
  • high-volume vaccine production
  • multilateral programme supply
  • legacy and expanded vaccine portfolio
What does not
  • profitability
  • R&D investment
  • domestic market share
  • pricing strategy
Study it if
  • public health procurement specialists
  • emerging-market manufacturing analysts
  • global health logisticians
Skip it if
  • VC investors assessing growth potential
  • IP strategists
  • biotech innovators
Who should study it, and who should skipHide who it is for
The written brief1 min read

What the company or idea is

Serum Institute of India is a private biotechnology and biopharmaceuticals company founded in 1966 in Pune, India, and owned by the Cyrus Poonawalla Group.

How it actually makes money

It sells vaccines and biopharmaceutical products — antisera, blood plasma, and hormone products — to global public health programmes and national immunisation systems.

What works

It manufactures at scale across multiple vaccine classes — including DPT, MMR, tetanus antitoxin, snake antivenom, influenza, meningococcal, and combination vaccines — and supplies them to major international public health programmes.

What does not

The material says nothing about pricing, margins, cost of goods sold, R&D spend, or domestic Indian market share. It does not establish whether it profits from high-income markets or relies entirely on volume-driven contracts with multilateral buyers.

What to take from it

Its significance lies in being the world’s largest vaccine manufacturer by volume — a function of production capacity, regulatory approvals, and long-term supply agreements with WHO, UNICEF, and PAHO — not innovation or IP ownership.

Is it worth your time

Yes, if you are studying how scale in vaccine manufacturing is achieved without state ownership, or how a private firm becomes infrastructure for global public health.

Same desk · Companies4 of 325
10:03
Sanofi2004Sanofi is a French pharmaceutical company founded in 1973. In 2004, it merged with Aventis to form Sanofi-Aventis — a deal driven by scale, not science. It makes money from prescription drugs and vaccines, not breakthroughs. Its strength lies in manufacturing, marketing, and regulatory reach — not discovery velocity.
12:05
Eli Lilly and CompanyEli Lilly · 1875Eli Lilly and Company is a foundational case in how business infrastructure — not just discovery — creates pharmaceutical power. Its early bets on quality control, prescription gatekeeping, and regulation were deliberate, profitable, and durable. The sources confirm no modern financials or valuations, so analysis must stay anchored in its documented methods and milestones.
11:06
Sinopharm (company)1998Sinopharm is a Chinese state-owned enterprise founded on November 26, 1998. It developed the BBIBP-CorV inactivated virus COVID-19 vaccine, which showed 78.1% efficacy against symptomatic disease and 100% against severe disease in peer-reviewed Phase III trials. In 2009, it merged with China National Biotec Group. Its subsidiary Wuhan Institute of Biological Products was fined in November 2017 for selling 400,520 ineffective DPT vaccines.
10:34
Airbus1998Airbus in 1998 was a consortium — not a company — sustained by national governments and bound by treaty, not equity. Its money came from airliner sales, but its structure reflected diplomacy more than business logic. It worked because Europe prioritised strategic autonomy over market efficiency. It failed as a unified enterprise until it abandoned the consortium model entirely. The lesson is structural: scale in aerospace is political first, economic second.
Up next in Business

Shanghai Stock Exchange

1990 · 9:55

Asia’s biggest stock exchange isn’t free—it’s run like a policy instrument.

Next brief →Back to Companies
9:55